Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(reteplase)
474 results
  • Improving the solubility, activity, and stability of reteplase using in silico design of new variants. [Journal Article]
    Res Pharm Sci 2019; 14(4):359-368Ghaheh HS, Ganjalikhany MR, … Mir Mohammad Sadeghi H
  • Reteplase (recombinant plasminogen activator, r-PA) is a thrombolytic agent recombined from tissue-type plasminogen activator (t-PA), which has several prominent features such as strong thrombolytic ability and E. coli expressibility. Despite these outstanding features, it demonstrates reduced fibrin binding affinity, reduced stimulation of protease activity, and lower solubility, hence higher ag…
  • Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase. [Journal Article]
    Adv Emerg Nurs J 2019 Jul/Sep; 41(3):271-278Dillon GM, Stevens S, … Purdon B
  • Alteplase is a tissue plasminogen activator approved for treating acute ischemic stroke (AIS), acute myocardial infarction (AMI), and acute massive pulmonary embolism. Two additional tissue plasminogen activators, tenecteplase and reteplase, are also approved for AMI treatment. However, neither tenecteplase nor reteplase is approved for AIS treatment. The U.S. Food and Drug Administration has rec…
  • Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism. [Review]
    Eurasian J Med 2019; 51(2):186-190Ucar EY
  • Thrombolytic treatment accelerates the dissolution of thrombus in acute pulmonary thromboembolism (PTE) and is potentially a lifesaving treatment. High-risk PTE is the clearest indication for this therapy, and its use in intermediate-risk cases is still controversial. A PTE response team may enable a rapid and effective determination of risk and treatment in these controversial clinical cases. Ap…
  • Reteplase: Structure, Function, and Production. [Review]
    Adv Biomed Res 2019; 8:19Mohammadi E, Seyedhosseini-Ghaheh H, … Mir Mohammad Sadeghi H
  • Thrombolytic drugs activate plasminogen which creates a cleaved form called plasmin, a proteolytic enzyme that breaks the crosslinks between fibrin molecules. The crosslinks create blood clots, so reteplase dissolves blood clots. Tissue plasminogen activator (tPA) is a well-known thrombolytic drug and is fibrin specific. Reteplase is a modified nonglycosylated recombinant form of tPA used to diss…
  • Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase. [Review]
    Expert Opin Drug Saf 2019; 18(2):87-96Chester KW, Corrigan M, … Dillon GM
  • Alteplase, reteplase, and tenecteplase are tissue plasminogen activators (TPA) approved for the management of acute myocardial infarction. Only alteplase is also approved for the treatment of acute ischemic stroke (AIS). The US Food and Drug Administration has received reports of accidental administration of tenecteplase or reteplase instead of alteplase in patients with AIS, which can result in …
New Search Next